SAN DIEGO, Sept. 26, 2017 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, announced today that Nick Lowery, new NFL spokesman for portfolio company Kannalife Sciences, will be interviewing on FOX Business' Varney & Co. Tuesday, Sept. 26, at 9:15 a.m. ET. He will be speaking about his work with Kannalife and current research about Chronic Traumatic Encephalopathy (CTE).
CTE is a degenerative neurological disease caused by repeated head trauma and is only diagnosed with certainty in post-mortem examinations. CTE can lead to symptoms like violent mood swings, depression and other cognitive difficulties. The evidence of severe CTE was seen last week in the latest brain autopsy of NFL player and New England Patriots Tight-End Aaron Hernandez. Currently, CTE can only be definitively diagnosed by direct tissue examination after death. Since not much is known about this debilitating disease, treatment and prevention options are currently bleak, while interesting research options are on the horizon.
"We are extremely proud to have Nick speaking with Varney & Co. about how devastating and debilitating CTE can be – and also about the solutions that are on the way," said Medical Marijuana, Inc. CEO Dr. Stuart Titus. "We are very glad to have such a passionate and educated spokesman to inform the world about this newly discovered and researched disease."
Varney & Co. is a news and talk show on the Fox Business Network, hosted by British-American economic and political commentator Stuart Varney. The show includes coverage of market events, current events and interviews.
About Kannalife Sciences
Kannalife Sciences, Inc. ("Kannalife"), is a bio-pharmaceutical and phyto-medical company involved in the research and development of novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants. Kannalife Sciences currently holds an exclusive license with National Institutes of Health – Office of Technology Transfer ("NIH-OTT") for the Commercialization of U.S. Patent #6630507, "Cannabinoids as Antioxidants and Neuroprotectants" (the "'507 Patent"). Kannalife is currently conducting research and development at the Bucks County Pennsylvania Biotechnology Center in Doylestown, PA, for a target drug candidate to treat Hepatic Encephalopathy ("HE") and Chronic Traumatic Encephalopathy ("CTE"). HE and CTE are both oxidative stress related diseases that affects the cognitive and behavioral functions, and the wellness of the brain.
About Medical Marijuana, Inc.:
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.'s portfolio and investment companies, visit www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.'s video statement, click here. Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.
FORWARD-LOOKING DISCLAIMER AND DISCLOSURES
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.
The statements in this press release have not been evaluated by the Food and Drug Administration (FDA) and are not intended to diagnose, treat or cure any disease. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act. The Company does sell and distribute hemp-based products.
Public Relations Contact:
Chief Executive Officer
SOURCE Medical Marijuana, Inc.